Literature DB >> 11991257

Up-regulation of central mu-opioid receptors in a model of hepatic encephalopathy: a potential mechanism for increased sensitivity to morphine in liver failure.

Nora V Bergasa1, Richard B Rothman, Erik Mukerjee, John Vergalla, E Anthony Jones.   

Abstract

Increased GABA-mediated neurotransmission, reported to occur in hepatic encephalopathy (HE), is associated with a decrease in the release of Met-enkephalin and the expression of its coding gene in the brain. Furthermore, patients with cirrhosis and a history of HE exhibit increased sensitivity to the neuroinhibitory effects of morphine. Thus, there is a rationale to study the status of the endogenous opioid system in HE. The aim of this study was to determine whether mu-opioid receptors in the brain are up-regulated in a well characterized model of HE. Binding parameters of mu-opioid receptors were derived by assaying the binding of the opiate agonist [3H]-tyr-D-Ala-Gly-N-Methyl-Phe-Gly-ol (DAMGO) to brain membranes from rats with precisely defined stages of HE and control animals. The mean density of mu-opioid receptor sites (Bmax) in rats with stage II, III, and IV HE was 15, 29, and 33% higher, respectively, than the corresponding control value (p<0.01). In addition, the affinity of mu opioid receptors for the agonist (1/Kd) also increased with progression of HE (mean for stage IV HE vs. corresponding control mean, p<0.01). In conclusion, in liver failure, increased density and affinity of central mu-opioid receptors in the brain may: (i) be the basis for the documented increased sensitivity to opiate agonists; and (ii) occur as a consequence of increased GABAergic tone reducing neuronal synthesis and release of opioid agonist peptides.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11991257     DOI: 10.1016/s0024-3205(02)01487-x

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  12 in total

1.  Up-regulation of mu-opioid receptors in the spinal cord of morphine-tolerant rats.

Authors:  Subrata Basu Ray; Himanshu Gupta; Yogendra Kumar Gupta
Journal:  J Biosci       Date:  2004-03       Impact factor: 1.826

2.  Cirrhosis Inpatients Receive More Opioids and Fewer Nonopioid Analgesics Than Patients Without Cirrhosis.

Authors:  Jessica B Rubin; Jennifer C Lai; Amy M Shui; Samuel F Hohmann; Andrew Auerbach
Journal:  J Clin Gastroenterol       Date:  2021-10-14       Impact factor: 3.062

3.  Using Intervention Mapping to Develop a Novel Pain Self-Management Intervention for People with Cirrhosis.

Authors:  Shari S Rogal; Matthew J Chinman; William DeMonte; Sandra Gibson; Stephanie Hoyt-Trapp; Gloria J Klima; Naudia L Jonassaint; Jane M Liebschutz; Kevin L Kraemer; Jessica Merlin
Journal:  Dig Dis Sci       Date:  2022-02-11       Impact factor: 3.487

Review 4.  [Opioids during anesthesia in liver and renal failure].

Authors:  C Höhne; B Donaubauer; U Kaisers
Journal:  Anaesthesist       Date:  2004-03       Impact factor: 1.041

Review 5.  Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics.

Authors:  Mellar Davis
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

6.  Analgesics in patients with hepatic impairment: pharmacology and clinical implications.

Authors:  Marija Bosilkovska; Bernhard Walder; Marie Besson; Youssef Daali; Jules Desmeules
Journal:  Drugs       Date:  2012-08-20       Impact factor: 9.546

7.  Opioid prescriptions are associated with hepatic encephalopathy in a national cohort of patients with compensated cirrhosis.

Authors:  Andrew M Moon; Yue Jiang; Shari S Rogal; Elliot B Tapper; Sarah R Lieber; A Sidney Barritt
Journal:  Aliment Pharmacol Ther       Date:  2020-01-21       Impact factor: 8.171

8.  Characteristics of Opioid Prescriptions to Veterans With Cirrhosis.

Authors:  Shari S Rogal; Lauren A Beste; Ada Youk; Michael J Fine; Bryan Ketterer; Hongwei Zhang; Steven Leipertz; Maggie Chartier; Chester B Good; Kevin L Kraemer; Matthew Chinman; Timothy Morgan; Walid F Gellad
Journal:  Clin Gastroenterol Hepatol       Date:  2018-10-17       Impact factor: 11.382

9.  Abnormal nociception and opiate sensitivity of STOP null mice exhibiting elevated levels of the endogenous alkaloid morphine.

Authors:  Alexandre Charlet; Arnaud H Muller; Alexis Laux; Véronique Kemmel; Annie Schweitzer; Jean-Christophe Deloulme; Denise Stuber; François Delalande; Enrica Bianchi; Alain Van Dorsselaer; Dominique Aunis; Annie Andrieux; Pierrick Poisbeau; Yannick Goumon
Journal:  Mol Pain       Date:  2010-12-20       Impact factor: 3.395

Review 10.  The effects of beta-endorphin: state change modification.

Authors:  Jan G Veening; Henk P Barendregt
Journal:  Fluids Barriers CNS       Date:  2015-01-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.